rasagiline / Generic mfg. - LARVOL DELTA

From de-novo molecule design to behavior and transcriptomics: An in-silico:in-vivo integrated platform for pre-screening neurodegenerative disease drugs (Neuroscience 2026) - "To validate the in-vivo pipeline, clinically informed drug selection included successful translational compounds (Levodopa, Amantadine, Pramipexole), failed phase III candidates (4-Aminopyridine, Isradipine), and Rasagiline as a translational control, given its efficacy in mammals but absence of a suitable molecular target in Drosophila. Candidates are filtered by predicted pharmacokinetic and safety profiles, then advanced into the proprietary Drosophila platform for toxicology, survival, behavior, and transcriptomic readouts, creating a closed loop in-silico:in-vivo validation. Together, this integrated platform offers a scalable, mechanistically informed strategy for pre-screening both known and de-novo molecules for neurodegenerative disease pipelines."

Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease

Comparative Efficacy and Safety of Treatments for Parkinson's Disease With Depression: A Systematic Review and Bayesian Model-Based Network Meta-Analysis. (PubMed, Brain Behav) - "Our findings indicate that selective serotonin reuptake inhibitors (SSRIs), dopamine agonists, and rTMS suggest relative efficacy and an acceptable safety profile in treating PD with depression. However, given the limited evidence for several interventions, these findings should be interpreted cautiously and confirmed in larger, multicenter studies."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Movement Disorders • Parkinson's Disease • Psychiatry

Meta-analysis and pharmacoeconomic study of rasagiline versus selegiline in the treatment of Parkinson's disease. (PubMed, Ann Med) - "However, at its current pricing, rasagiline is not cost-effective. Significant price reductions or definitive proof of long-term superiority are required to justify its economic value."

Clinical • HEOR • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Span60/Cholesterol Niosomal Formulation as a Transport Vehicle for L-DOPA and Rasagiline Delivery with Potent In Vitro Neuroprotective Effect. (PubMed, Appl Biochem Biotechnol) - "L-DOPA and Rasagiline-loaded niosomes demonstrated effective delivery, neuroprotection, and gene modulation with minimal toxicity. These findings demonstrate the potential of niosomal encapsulation of L-DOPA and Rasagiline in an in vitro Parkinson's disease model, and indicate the necessity for further mechanistic and in vivo investigation."

Journal • Preclinical • CNS Disorders • Movement Disorders • Parkinson's Disease • LRRK2 • PINK1

An In Vivo Single-Vesicle Electrochemistry Enables Monitoring Vesicular Dopamine Dynamics and Pharmacological Rescue. (PubMed, Angew Chem Int Ed Engl) - "Rasagiline treatment partially restored vesicular DA storage and release dynamics toward physiological levels, suggesting a protective modulation of vesicle function. This in vivo electrochemical method offers a single vesicle-resolved analytical platform for dissecting vesicular heterogeneity and dysfunction directly in intact neural systems, thereby bridging single-vesicle chemistry with in vivo neurobiology and opening new avenues for mechanistic studies of neurodegeneration and therapeutic intervention."

Journal • Preclinical • Anesthesia • CNS Disorders • Movement Disorders • Parkinson's Disease

A successful switch from rasagiline to safinamide in a 49-year-old female with early-onset Parkinson's disease: a case report and review of literature. (PubMed, Naunyn Schmiedebergs Arch Pharmacol) - "The case of a 49 year-old female patient with early-onset Parkinson's disease who was transitioned from 1 mg rasagiline to 50 mg safinamide with a three-day washout period is described; afterwards, we review the relevant literature and current recommendations. We believe this paper will be valuable to clinicians and researchers managing such scenarios, and perhaps motivate further larger sample size studies, or help inform best practices in the treatment of Parkinson's disease."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Three Randomized Controlled Trials In Amyotrophic Lateral Sclerosis: A Comparative Analysis (ENCALS 2026) - "Despite extensive therapeutic efforts, riluzole remains the only drug demonstrating clinical efficacy in sporadic ALS, with the recent approval of tofersen for SOD1-associated ALS representing a mutation-specific advance. This study aimed to identify methodological and clinical parameters that may improve the design and statistical robustness of future ALS trials.Material and methods A comparative analysis was conducted across three investigator-initiated randomized controlled trials (RCTs) performed by the German Network for ALS and Motoneuron Diseases between 2008 and 2017: GERP-ALS (pioglitazone), RAS-ALS (rasagiline), and LIPCAL-ALS (HCFD)...Notably, placebo cohorts across the three trials demonstrated highly comparable survival trajectories.Conclusion These findings identify actionable methodological parameters that may enhance recruitment efficiency, patient stratification, and statistical power in future ALS trials. Furthermore, the comparable survival patterns..."

Clinical • Amyotrophic Lateral Sclerosis • CNS Disorders • RAS

A Case Report of a Novel Alpha-Synuclein Vaccine (TRB-001) in a Parkinson's Patient: Safe Administration and Induction of a High-Titer, High-Avidity Functional Antibody Response. (PubMed, Vaccines (Basel)) - "Results obtained suggest that this new class of vaccines may yield Ab responses comparable in magnitude and target avidity to the therapeutic setting of monoclonal Abs. TRB-001 is currently being translated to a randomized, placebo-controlled Phase 1B study."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease

Dopamine-Enhancing Therapies and Risk of Neovascular AMD Conversion: A Target Trial Emulation. (PubMed, Am J Ophthalmol) - "In this cohort study, levodopa ± carbidopa use was associated with lower 3-year risk of conversion to nAMD in two independent matched comparisons, whereas DRD2 agonists were not associated with significant differences in risk. These findings suggest dopaminergic signaling may influence AMD progression and warrant further prospective investigation."

Journal • Age-related Macular Degeneration • Macular Degeneration • Ophthalmology • Retinal Disorders • DRD2

Combination therapy of levodopa with safinamide is more effective than with rasagiline and zonisamide in Asian Parkinson's disease patients with motor fluctuations: a systematic review and network meta-analysis of randomized controlled trials. (PubMed, J Neurol) - "The findings suggest that levodopa in combination with safinamide 100 mg is more efficacious than combinations with rasagiline 1 mg or zonisamide 25 mg for alleviating motor fluctuations and improving motor symptoms in Asian PD patients, and shows a more favourable (though not statistically significant) trend compared with zonisamide 50 mg."

Clinical • Journal • Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

HNC364-A102: Relative Bioavailability Study of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=30 | Active, not recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Movement Disorders • Parkinson's Disease

Design, Synthesis, and Evaluation of Coumarin-Rasagiline Hybrids as Multifunctional Neuroprotective Agents. (PubMed, ChemMedChem) - "Docking studies and molecular dynamics simulations provide additional support for the experimental data. Collectively, these findings provide renewed evidence for the therapeutic potential of coumarin-rasagiline hybrids as multifunctional agents for the treatment of neurodegenerative diseases."

Journal • CNS Disorders

Treatment stability comparison among different ADD-ON therapies in fluctuating Parkinson's disease patients: the role of clinical and demographic factors. (PubMed, J Neural Transm (Vienna)) - "All ADD-ON therapies showed comparable treatment stability and tolerability. No statistically significant sex-related differences were observed, although a trend toward more frequent therapy modifications was found in female patients."

Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • COMT

Relative Bioavailability Study of HNC364 Injectable Suspension (clinicaltrials.gov) - P1 | N=30 | Recruiting | Sponsor: Guangzhou Henovcom Bioscience Co. Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Jun 2026 ➔ Dec 2026 | Trial primary completion date: May 2026 ➔ Dec 2026

Enrollment open • Trial completion date • Trial primary completion date • CNS Disorders • Movement Disorders • Parkinson's Disease

Exploiting the Danio rerio model and bioinformatics to explore the effects and molecular networks of Parkinson's disease drugs in human melanoma. (PubMed, Eur J Cell Biol) - "Drugs commonly used in Parkinson's disease treatment, including amantadine, rasagiline and carbidopa (C-DOPA), have gained attention for their potential anticancer properties. Further development and investigation are needed to explore the potential effects of PD drugs on human melanoma and to better understand the complex association between both diseases. The use of zebrafish as a xenotransplantation model offers great opportunities to investigate such drugs and their effects on melanoma cells in a living organism."

Journal • CNS Disorders • Genetic Disorders • Melanoma • Movement Disorders • Oncology • Parkinson's Disease • Skin Cancer • Solid Tumor • Transplantation

The Safety and Efficacy of Monoamine Oxidase-B Inhibitors as Add-on Therapy to Dopamine Agonists for the Treatment of Parkinson’s Disease: A Systematic Review and Network Meta-analysis of Randomized Controlled Trials (AAN 2026) - "Background Parkinson's disease (PD) is a neurodegenerative disease, treated with carbidopa/levodopa or a dopamine agonist...They can be irreversible (selegiline and rasagiline) or reversible (safinamide)...Conclusions Selegiline (10mg/day) and safinamide (100mg) offer good therapeutic benefit as add-on therapy for PD. However, safinamide (100mg) has a relatively better safety profile as compared to selegiline (10mg/day). Further research should emphasize on long-term effects of these drugs through longitudinal studies focusing on patient-reported outcomes."

Retrospective data • Review • CNS Disorders • Movement Disorders • Parkinson's Disease

Drug repurposing for disease-modifying effects in multiple system atrophy. (PubMed, Transl Neurodegener) - "We focus on agents targeting key pathogenic mechanisms in MSA-including α-synuclein aggregation (e.g., sirolimus/rapamycin, rifampicin, lithium, nilotinib, epigallocatechin gallate), neuroinflammation (e.g., minocycline, intravenous immunoglobulin), mitochondrial dysfunction and excitotoxicity (e.g., ubiquinol, rasagiline, safinamide, riluzole), and impaired neurotrophic support (e.g., fluoxetine/selective serotonin reuptake inhibitors, insulin, exendin-4). Nonetheless, ongoing studies and emerging approaches such as combination therapies hold promise. Continued exploration of repurposed therapies, along with improved trial design and biomarker development, is warranted to finally achieve a disease-modifying treatment for MSA."

Journal • Review • CNS Disorders • Inflammation • Metabolic Disorders • Movement Disorders • Multiple System Atrophy

Fatigue in Parkinson's disease and management with NIBS. (PubMed, Neurol Sci) - "This review summarizes the clinical features, diagnostic criteria, and current therapeutic strategies for PD-related fatigue,with a focus on the emerging role of NIBS. Future research should prioritize well-designed, large-scale randomized controlled trials tooptimize stimulation parameters and validate the long-term efficacy of NIBS in fatigue management for PD patients."

Journal • Review • CNS Disorders • Fatigue • Movement Disorders • Parkinson's Disease

Case Report: Pharmacogenetically-triggered fatal serotonin syndrome following sequential serotonergic therapy in Parkinson's disease: a case highlighting the role of CYP2D6*10/*10 genotype and multifactorial drug interactions. (PubMed, Front Psychiatry) - "We present a fatal case of SS complicated by multiple organ failure in a 72-year-old patient with Parkinson's disease following the sequential administration of two selective serotonin reuptake inhibitors (sertraline and escitalopram) while on a stable regimen of the monoamine oxidase-B inhibitor rasagiline. This report underscores the critical importance of pre-emptive pharmacogenomic screening in patients receiving complex polypharmacy, particularly when combining drugs with serotonergic properties. It also serves as a critical warning that even selective MAO-B inhibitors can precipitate life-threatening interactions with SSRIs in genetically susceptible individuals, thereby informing more stringent personalized therapeutic strategies."

Biomarker • Journal • CNS Disorders • Movement Disorders • Parkinson's Disease • Renal Disease

EFFECTS OF MAO-B AND COMT INHIBITORS ON SLEEP DISTURBANCES IN PARKINSON'S DISEASE: A NETWORK META-ANALYSIS (ADPD 2026) - "Inclusion criteria involved (1) patients with PD, (2) intervention/comparator consisting of MAO-B inhibitors (safinamide, rasagiline, or selegiline) and COMT inhibitors (opicapone, entacapone, or tolcapone), and (3) outcomes of improvement in parameters for subjective and objective sleep in randomized controlled trials and cohort studies. A total of 529 articles were identified during the initial search, and we ultimately conducted an NMA focusing on the final seven studies. Evidence has shown that safinamide is effective in improving objective sleep parameters in patients with PD. However, given the paucity of evidence and controlled, long-term studies, the effects of MAO-B and COMT inhibitors on sleep disturbances remain unclear. More high-quality studies will be needed and should enable clinicians to provide personalized medicine based on sleep profiles."

Retrospective data • CNS Disorders • Movement Disorders • Parkinson's Disease • Sleep Disorder • COMT

EVALUATING REGIONAL VOLUMETRIC MRI BIOMARKERS AND SEGMENTATION METHODS FOR DISEASE PROGRESSION ASSESSMENT IN MULTIPLE SYSTEM ATROPHY (ADPD 2026) - P2, P3 | "Segmentation methods were further validated by assessing their scan–rescan repeatability. MRI and UMSARS data from 42 patients with MSA in 2 multicenter trials (Rasagiline for MSA, NCT00977665; PROMESA, NCT02008721) were analyzed using multiple segmentation FreeSurfer (v6.0.0 and v8.1.0; cross-sectional and longitudinal), SynthSeg, FastSurfer, and 2 in-house deep learning–based tools... This study provides the first systematic comparison of segmentation methodologies for assessing longitudinal brain volume changes in MSA. Regional volumetric MRI, when analyzed with contemporary tools, yields highly sensitive markers of disease progression, surpassing clinical scales such as UMSARS in terms of effect sizes. These findings support the use of volumetric MRI as a surrogate endpoint of disease progression in future MSA clinical trials."

Biomarker • CNS Disorders • Movement Disorders • Multiple System Atrophy

A CASE OF ACUTE DYSPHAGIA IN PROXIMAL MYOTONIC MYOPATHY WITH BENIGN TREMULOUS PARKINSONISM : DOUBLE JEOPARDY OF SWALLOWING (ADPD 2026) - "FT-CIT PET study revealed a marked bilateral presynaptic dopaminergic deficit, and rasagiline treatment was initiated. For more than 3 years, he had been keeping an independent daily activity with regular exercise (bicycling and weight training)... We report a rare case of acute dysphagia in a patient with PROMM coexisting with BTP. This case emphasizes that rapid progressive symptoms like severe swallowing dysfunction could develop in a patient with complex neuromuscular and movement disorders."

Clinical • Alopecia • Atrial Fibrillation • Cardiovascular • Cataract • CNS Disorders • Gastrointestinal Disorder • Genetic Disorders • Movement Disorders • Muscular Atrophy • Muscular Dystrophy • Myositis • Myotonic Dystrophy • Ophthalmology • Otorhinolaryngology • Parkinson's Disease

COMPARATIVE COGNITIVE EFFECTS OF MAO-B INHIBITORS IN PARKINSON'S DISEASE (ADPD 2026) - "We aimed to compare the effects of selegiline, rasagiline, and safinamide on global cognitive function and specific cognitive domains in patients with PD. Comprehensive literature searches in PubMed, Embase, and Cochrane Library identified randomized controlled trials (RCTs) assessing cognitive outcomes in PD patients treated with MAO-B inhibitors. Among MAO-B inhibitors, only rasagiline was associated with enhanced overall cognitive performance in PD, but domain-specific improvements were largely absent. These findings indicate that cognitive benefits beyond motor symptom control remain limited, and highlight the need for future long-term studies with domain-focused assessments to delineate therapeutic roles for MAO-B inhibitors in cognitive outcomes for PD patients."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Movement Disorders • Parkinson's Disease

Case Report: A possible novel adult-onset, progressive MAO-A hypofunction. (PubMed, Front Neurosci) - "The nature of the pathophysiology was then tested first by fractionated plasma catecholamine assays, performed at baseline and again using entacapone challenge to suppress catechol-O-methyltransferase function. Treatment consistent with the hypothesis consisted of rasagiline or selegiline combined with carvedilol. This treatment relieved all symptoms."

Journal • COMT

Consensus Molecules Associated with Parkinson's Disease. (PubMed, Neurol Int) - "Drugs include L-dopa (49%), carbidopa (63%), benserazide (50%), entacapone (74%), tolcapone (56%), rasagiline (76%), selegiline (46%), pargyline (4%), ropinirole (61%), pramipexole (56%), lisuride (27%), cabergoline (16%), bromocriptine (12%), and zonisamide (9%). Adjunctive therapies include droxidopa (33%), trihexyphenidyl (28%), biperiden (17%), amantadine (24%), memantine (7%), rivastigmine (13%), donepezil (6%), galantamine (4%), domperidone (6%), clonazepam (4%), tetrabenazine (16%), mazindol (13%), quetiapine (6%), and clozapine (4%). Contraindicated drugs include haloperidol (4%), sulpiride (3%), and methyldopa (6%)...Chemical inducers of PD include 6-hydroxydopamine (40%), N-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP, 78%), tetrahydropyridine (77%), probenecid (4%), quinolinic acid (4%), 1,2,3,4-tetrahydroisoquinoline (TIQ, 16%), salsolinol (32%), rotenone (25%), and β-Methylamino-L-alanine (BMAA, 29%). Notably, our study highlights conditional essential..."

Journal • Review • CNS Disorders • Movement Disorders • Parkinson's Disease